1. Home
  2. GMDA

GMDA

Gamida Cell Ltd.

Logo Gamida Cell Ltd.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

Founded: 1998 Country:
Israel
Israel
Employees: N/A City: JERUSALEM
Market Cap: 5.3M IPO Year: 2018
Target Price: $4.75 AVG Volume (30 days): 9.4M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.57 EPS Growth: N/A
52 Week Low/High: $0.03 - $2.51 Next Earning Date: 05-13-2024
Revenue: $1,784,000 Revenue Growth: N/A
Revenue Growth (this year): 796.52% Revenue Growth (next year): 1080.32%

Share on Social Networks: